| Followers | 66 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Monday, June 12, 2023 2:12:00 PM
In the grand scheme only having the full UK approval in 2023 is lousy but about the best we can expect this point.
Only getting a $2.50 SP with an approval shows how badly managed this company truly is. We’ve achieved higher SPs with far less.
It is important to remember that even after the October 5, 2020 let down on TLD release not what even pessimistic folks who still believe in the science would have really expected approval to take 3 years from the data lock announced that day. Anyone who said it would be 3 years would have been viciously attacked and yet here we are.
Sure if you focus on a cherry picked small number of late coming shareholders then yes they only waited maybe 3 years for a good payout. This CEO has poorly served the vast majority of those who invested during her tenure.
Also, the long term has arrived and accountability means NWBO does not get to keep reframing the meaning of that or kicking the real payoff endlessly into the future on one flimsy pretext or another.
Only getting a $2.50 SP with an approval shows how badly managed this company truly is. We’ve achieved higher SPs with far less.
It is important to remember that even after the October 5, 2020 let down on TLD release not what even pessimistic folks who still believe in the science would have really expected approval to take 3 years from the data lock announced that day. Anyone who said it would be 3 years would have been viciously attacked and yet here we are.
Sure if you focus on a cherry picked small number of late coming shareholders then yes they only waited maybe 3 years for a good payout. This CEO has poorly served the vast majority of those who invested during her tenure.
Also, the long term has arrived and accountability means NWBO does not get to keep reframing the meaning of that or kicking the real payoff endlessly into the future on one flimsy pretext or another.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
